DenmarkDenmark

Exiqon secures Euro17m in round C

10.07.2005

Copenhagen - The Danish real-time PCR specialist Exiqon A/S has completed a third round of financing at the beginning of June providing some Euro17 million in additional funding. The funding is earmarked for developing products from the company's growing product portfolio, for increasing sales and marketing capabilities and for repaying loans. This brings the total funding since incorporation in 1996 to Euro31 million. The current investors include Teknoinvest as lead investor and Scandinavian Life Science Venture, Nobel Group, LD Pensions, BioFund, and Danske Bank, all of which participated in the previous round of financing.
The company has recently completed a major distribution agreement with Roche Diagnostics for Exiqon's ProbeLibrary™ real-time PCR kits, addressing one of the largest market segments within life science. Exiqon is now strengthening its product portfolio as well as sales and marketing efforts and is launching a number of new miRCURY™ products for microRNA analysis as well as products in other high-growth areas. “Getting high-value products on the market is essential to our business and it has been the main focus for Exiqon during the past couple of years” says Exiqon's President and CEO Lars Kongsbak.

DenmarkDenmark

26.11.2005

Copenhagen - The Danish medicines agency, the DKMA, has restated the requirement for imported pharmacological products to have a GMP certificate. Denmark is unique within the EU in that it requires that all imported...

DenmarkDenmark

26.11.2005

Copenhagen - Danish scientists from Aresa Biodetection ApS, a Copenhagen-based company, has developed a bomb and landmine detection plant that is soon expected to be introduced in the market. In collaboration with the Danish...

DenmarkDenmark

26.11.2005

Copenhagen - Gastrotech Pharma A/S has been acquired by the US biotech company Dor BioPharma Inc. in a stock transaction valued around $9 million. Gastrotech will be eligible to receive an additional cash or stock milestone...

DenmarkDenmark

28.09.2005

Copenhagen - To provide viable capital markets for small unlisted companies, the Nordic stock exchange OMX will establish an alternative marketplace in the nordic region for companies that are not ready for an official listing at...

DenmarkDenmark

28.09.2005

Copenhagen - NatImmune A/S and Enzon Pharmaceuticals, Inc. at the beginning of October have signed a licence agreement for NatImmune's lead development product, recombinant human Mannan-Binding Lectin (rhMBL). The therapeutic...

DenmarkDenmark

28.09.2005

Copenhagen/New Haven - TopoTarget A/S (Copenhagen, Denmark) and CuraGen Corp. (USA) have announced the initiation of patient dosing in a Phase Ib open-label, multi-center clinical trial evaluating PXD101, a small molecule histone...

DenmarkDenmark

12.08.2005

Copenhagen - Recently floated TopoTarget A/S has received a $4.8 million (Euro4 million) milestone payment from Cura-Gen Corp. as the ongoing Phase II clinical trial of PXD101 for the treatment of the serious blood cancer,...

DenmarkDenmark

12.08.2005

Reykjavik - Actavis Group, an international generic pharmaceuticals company operating from Iceland, announced that the acquisition of Amide Pharmaceuticals, Inc., a privately owned US generic pharmaceuticals company based in New...

DenmarkDenmark

12.08.2005

Bagsvaerd - First half figures for Novozymes A/S reveal that the number one food enzyme firm continues to gain from healthy sales to the baking industry. Overall, turnover for the enzymes business improved by 3% to DKK 2.88...

DenmarkDenmark

12.08.2005

Copenhagen - The US Patent and Trademark Office has issued a patent to Bavarian Nordic A/S that further strengthens its intellectual property position on MVA. The new patent “Modified vaccinia ankara virus variant”, US Patent No....

Displaying results 121 to 130 out of 194

< Previous 121-130 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/12/article/exiqon-secures-euro17m-in-round-c.html

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR102.0%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.3%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.1%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events